Search

everythinglearnresearchcommunity

for

Search:↓

A user discusses their experience with hair loss, noting they don't notice shedding despite using finasteride, minoxidil, and tretinoin. Others share similar experiences, suggesting that shedding varies and may not occur for everyone using these treatments.

The conversation discusses the effects of Pyrilutamide on hair growth after two months, with one person noting that while new hair regrowth isn't apparent, existing hair appears longer and thicker.

The conversation discusses hair shedding while using 0.5 mg dutasteride daily for 8.5 months, with users sharing experiences of shedding various hair lengths and thicknesses. It is suggested that shedding can be part of the hair cycle synchronization and may not indicate worsening hair loss.

The user experienced hair loss since 2021, tried various treatments, and is currently using oral minoxidil and finasteride since December 2024. They are experiencing shedding, which is common when starting or stopping treatments, and are advised to continue the current regimen as it may stabilize over time.

The user is considering switching from pyrilutamide to 0.025% topical finasteride due to concerns about effectiveness and past side effects from a scalp elixir. They aim to maintain hair until new treatments like breezula or GT00029 become available.

A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.

A user had a bad experience with MV Supplements when their Pyril powder and ethanol order leaked during shipping, making the products unusable. Despite contacting support and providing evidence, the company's return policy did not allow for a refund or replacement.

The conversation discusses organizing group buys and tracking progress for Kx-826 Pyrilutamide, a hair loss treatment. Participants express optimism about upcoming results and concerns about self-reporting bias.

The user is experiencing sleep issues after starting finasteride for hair loss and is considering using magnesium or melatonin to improve sleep. Other users suggest that sleep disturbances are a common side effect initially, but may improve over time.

The conversation is about a person's hair loss treatment routine, which includes Metformin, sleep in darkness, avoiding EMF at night, Nizoral, Dermarolling, Castor oil, and Collagen. They have observed less hair shedding and increased hair volume.

The post expresses frustration over the unavailability of pure topical finasteride in India despite the developed pharma industry. The user seeks advice on making it at home and its effectiveness.

Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.

PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.

The conversation discusses the safety study of PP405, emphasizing that early trials focus on safety rather than efficacy, and that any efficacy data from such a short study should be viewed skeptically. It also highlights that the information released is primarily for securing funding, and that meaningful efficacy results are expected in later phases.

The conversation is about purchasing KX-826 (Pyrilutamide) on Amazon, now called Koshine. A user mentioned their order is expected to arrive between August 22 and September 13.

RU58841 lacks FDA approval due to financial and safety concerns, including potential cardiological side effects. The company abandoned further research, and users report adverse effects like heart palpitations and gynecomastia.

A user is considering creating an all-in-one topical solution for hair loss, combining 0.25mg finasteride, 5% minoxidil, and 5% RU58841. They are seeking advice on its feasibility and absorption.

The conversation discusses a new model for understanding androgenetic alopecia (AGA), linking it to dietary and lifestyle factors similar to PCOS, and highlighting the role of DHT, vascular damage, and inflammation. Treatments mentioned include Minoxidil, finasteride, and RU58841.

The conversation discusses the potential market release of a hair loss treatment called GT20029 by Anageninc, with users expressing interest and discussing the importance of safety and effectiveness. Some users plan to contact Anageninc to show demand for the product.

Keratin fusion bonds are discussed as an alternative to clip-on hair patches for men with diffused thinning. The conversation explores different styling options for hair loss.

The user is experiencing a significant hair shed at 10 months but sees improvement compared to 4 months ago. They are using Hims products, Feel Confident shampoo, Nizoral, a light therapy cap, and The Ordinary hair serum.

The user experienced increased hair shedding after one month on 0.25 mg finasteride, despite initial improvement. This shedding may be a normal phase in the hair cycle and could improve in the coming months.

Phase II for TDM-105795 for Androgenic Alopecia is set to begin in April 2023. The study aims to evaluate the efficacy and safety of TDM-105795 in male subjects.

PP405 is a promising new treatment for hair loss. It performs three actions in one, potentially offering a cure.

The user has been using finasteride for four years and topical minoxidil with microneedling for a year but has not seen significant results in slowing hair loss. They are considering trying dutasteride despite concerns about its intensity, and others suggest trying oral minoxidil or combining treatments for better results.

The user is experiencing hair loss, possibly due to androgenic alopecia or telogen effluvium, and is considering treatments like Minoxidil, Finasteride, or RU58841. They also mention potential iron deficiency and sleep deprivation as contributing factors.

Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.

Switching from liquid to foam minoxidil may cause mild shedding, possibly due to differences in absorption. Returning to the original liquid formulation typically stabilizes shedding within a few weeks.

A user has been taking 0.5mg oral Finasteride daily for 8 months and is unsure if fine, soft, colorless hairs are regrowth. Other users suggest trying oral Minoxidil for faster results and mention their own experiences with oral treatments.

User plans to switch from oral to .005% topical finasteride, using a solvent from minoxidilmax and later Essengen-F. They will monitor DHT levels and seek advice on solvents and sleep caps.